1. NVS reported promising results for Fabhalta in treating PNH patients. 2. After 24 weeks, average Hb levels rose by 2.01 g/dL. 3. 92.7% of patients achieved Hb levels ≥12g/dL, showing efficacy. 4. Improved fatigue levels were reported, similar to the general population. 5. Data will be presented at the EHA Congress 2025.
The positive results from Fabhalta could drive increased demand and stock growth, similar to past treatments like eculizumab that saw price rebounds upon successful trial results. This suggests a favorable market reaction when the full data is presented.
The clinical success of Fabhalta in a significant patient population indicates strong market potential, influencing NVS's stock price positively. The improvements over existing treatments position Novartis favorably in a competitive landscape.
The results set the stage for future sales growth of Fabhalta, potentially dominating the PNH market long-term as patients shift from IV therapies, impacting NVS's financial outlook positively.